The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

May 31, 2018

Conditions
Polycystic Ovarian Syndrome
Interventions
OTHER

Tung's acupuncture

The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).

DRUG

Cyproterone acetate/ethinylestradiol (CPA/EE)

Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).

Trial Locations (1)

100039

Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing

All Listed Sponsors
lead

Beijing Hospital of Integrated Traditional Chinese and Western Medicine

OTHER

NCT02729545 - The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome | Biotech Hunter | Biotech Hunter